CERS - Cerus Corporation Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CERS

CERUS CORPORATION

NASDAQ

$2.29

▲ UP 0.66% (0.01)

KEY STATISTICS

Market Cap$456.11 M

52w High$3.47

52w Low$1.38

Dividend Yield—

Frequency—

P/E-76.25

Volume403.60K

Shares Out.201.52M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Vivek K. Jayaraman

COMPENSATION 2026

Salary$793,750

Stock Awards$2,242,585

Incentive Plan Pay$756,000

All Other Comp.$2,322

Total$3,794,657

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 31, 1997

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

268

PRICE TARGET

Target High$4.00

Target Low$4.00

Target Median$4.00

Target Consensus$4.00

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$63.25M

NOV

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

49.18%

HOLDERS

273

TOP 8 OF 273 · RANKED BY POSITION SIZE

Blackrock, Inc.

22.2M sh

$64.87M

Ark Investment Management LLC

Soleus Capital Management, L.P.

10.8M sh

$19.57M

Baker Bros. Advisors LP

10.0M sh

$18.22M

Elk Creek Partners, LLC

6.2M sh

$29M

Sumitomo Mitsui Trust Holdings, Inc.

5.7M sh

$9.04M

PRICE

$2.29 ▲ UP 0.66% (+$0.01)

About Cerus Corporation

https://www.cerus.com ↗

Cerus Corporation develops and commercializes the INTERCEPT Blood System to inactivate pathogens in blood components, enhancing transfusion safety worldwide.

INDUSTRY

Medical - Devices

A PRODUCT CERUS CORPORATION IS KNOWN FOR

INTERCEPT Blood System

The INTERCEPT Blood System is a leading pathogen reduction technology that inactivates viruses, bacteria, and parasites in blood components like platelets and plasma to ensure a safer global blood supply.

COMPETITORS

COMPETITOR

Cerus in 2025

SENTIMENT: + POSITIVE

PARTNERSHIP · DECEMBER 2025

Cerus Corporation Secures Major Partnership with Blood Centers of America, Expanding Nationwide Access to Blood Safety Technology

Cerus Corporation announced a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S., covering Cerus's entire INTERCEPT product line. This partnership is significant as BCA members produce approximately half of the U.S. platelet and cryoprecipitate supply, and the agreement is expected to drive expanded adoption of Cerus's pathogen reduction technology.

PARTNERSHIP · DECEMBER 2025 · ANNOUNCED

Cerus Corporation Enters into a Landmark Group Purchasing Agreement with Blood Centers of America to Expand Market Access for its Entire INTERCEPT Product Line

Cerus Corporation announced a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S., whose members represent approximately half of the nation's platelet and cryoprecipitate supply. [10, 11, 17, 36] This partnership is designed to broaden access to Cerus's pathogen reduction technology for platelets, plasma, and INTERCEPT Fibrinogen Complex (IFC) across BCA's extensive network of over 60 independent community blood centers. [10]